SMC5 and sarcoma: Our results also suggest that SMC1A and SMC2 are potential therapeutic targets for sarcoma, while levels of transcripts of SMC3, SMC4, SMC5 and SMC6 are potential prognostic markers to improve the survival rate and prognostic accuracy of sarcoma.